Reaction
Hepatic Neoplasm Malignant reporting signals
As of the last recalculation, Hepatic Neoplasm Malignant appears in 2,114 FAERS reports alongside 34 co-occurring drug terms. The strongest observed disproportionality signal is SORAFENIB (PRR 227.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sorafenib | 391 | 227.2 | 231.6 |
| Entecavir | 107 | 95.0 | 95.9 |
| Ursodiol | 120 | 57.5 | 57.8 |
| Peginterferon Alfa-2A | 79 | 14.9 | 14.9 |
| Rabeprazole | 31 | 14.0 | 14.0 |
| Ribavirin | 84 | 13.4 | 13.4 |
| Rabeprazole Sodium | 36 | 13.2 | 13.2 |
| Lamivudine | 39 | 12.6 | 12.7 |
| Spironolactone | 158 | 11.9 | 11.9 |
| Lamivudine Oral | 24 | 9.4 | 9.4 |
| Loperamide Hcl | 11 | 8.5 | 8.5 |
| Zidovudine | 11 | 8.1 | 8.1 |
| Atazanavir | 11 | 7.6 | 7.6 |
| Lactulose | 28 | 7.3 | 7.3 |
| Imatinib Mesylate | 20 | 7.1 | 7.1 |
| Pioglitazone | 29 | 6.7 | 6.7 |
| Ursosiol | 13 | 6.6 | 6.6 |
| Lopinavir And Ritonavir | 9 | 6.6 | 6.6 |
| Bicalutamide | 10 | 6.5 | 6.5 |
| Metformin Hcl | 32 | 5.8 | 5.8 |
| Erlotinib Hydrochloride | 7 | 5.5 | 5.5 |
| Exenatide | 28 | 5.3 | 5.3 |
| Rivastigmine | 10 | 5.2 | 5.2 |
| Derma Foam Excel Hand Sanitizer | 4 | 4.9 | 4.9 |
| Ethanol | 4 | 4.9 | 4.9 |
| Bosentan | 23 | 4.5 | 4.5 |
| Eltrombopag Olamine | 10 | 4.3 | 4.3 |
| Ranibizumab | 11 | 4.1 | 4.1 |
| Teriparatide | 46 | 4.1 | 4.1 |
| Sunitinib Malate | 15 | 3.8 | 3.8 |
| Tenofovir Disoproxil Fumarate | 12 | 3.6 | 3.6 |
| Romiplostim | 5 | 3.3 | 3.3 |
| Paricalcitol | 4 | 2.8 | 2.8 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 5 | 1.6 | 1.6 |